Galectin Therapeutics Update on the Impact of COVID-19
April 02, 2020 08:03 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the...
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
March 16, 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 16, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
February 20, 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced the appointment of Pol F. Boudes, M.D. to the...
Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
February 04, 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
December 09, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper...
Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
December 05, 2019 12:05 ET
|
Galectin Therapeutics Inc.
Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin, CEO,...
Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders
November 26, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H....
Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress
November 21, 2019 09:00 ET
|
Provectus Biopharmaceuticals Inc.
Full accrual of 21 checkpoint-naïve melanoma patientsNo safety concerns identified; no significant overlap of toxicities95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months10% CR...
Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
November 18, 2019 16:10 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer,...
Galectin Therapeutics Reports Q3 2019 Financial Results
November 12, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...